Document is current
Any future updates will be listed below
-
Authors
van der Spek, Ashley https://orcid.org/0000-0001-7136-0159
Stewart, Isobel D.
Kühnel, Brigitte
Pietzner, Maik
Alshehri, Tahani
Gauß, Friederike
Hysi, Pirro G. https://orcid.org/0000-0001-5752-2510
MahmoudianDehkordi, Siamak
Heinken, Almut
Luik, Annemarie I. https://orcid.org/0000-0001-7517-197X
Ladwig, Karl-Heinz https://orcid.org/0000-0002-0221-311X
Kastenmüller, Gabi
Menni, Cristina https://orcid.org/0000-0001-9790-0571
Hertel, Johannes
Ikram, M. Arfan https://orcid.org/0000-0003-0372-8585
de Mutsert, Renée
Suhre, Karsten https://orcid.org/0000-0001-9638-3912
Gieger, Christian https://orcid.org/0000-0001-6986-9554
Strauch, Konstantin
Völzke, Henry
Meitinger, Thomas
Mangino, Massimo https://orcid.org/0000-0002-2167-7470
Flaquer, Antonia
Waldenberger, Melanie
Peters, Annette https://orcid.org/0000-0001-6645-0985
Thiele, Ines https://orcid.org/0000-0002-8071-7110
Kaddurah-Daouk, Rima
Dunlop, Boadie W. https://orcid.org/0000-0002-4653-0483
Rosendaal, Frits R.
Wareham, Nicholas J. https://orcid.org/0000-0003-1422-2993
Spector, Tim D.
Kunze, Sonja
Grabe, Hans Jörgen https://orcid.org/0000-0003-3684-4208
Mook-Kanamori, Dennis O.
Langenberg, Claudia https://orcid.org/0000-0002-5017-7344
van Duijn, Cornelia M. https://orcid.org/0000-0002-2374-9204
Amin, Najaf https://orcid.org/0000-0002-8944-1771
- License Information
-
More Information
Article History
Received: 1 July 2022
Revised: 3 July 2023
Accepted: 3 July 2023
First Online: 26 July 2023
Competing interests
: The authors declare the following competing interests: AS is an employee and option holder of SkylineDx B.V.. Dennis Mook-Kanamori works as a part-time clinical research consultant for Metabolon, Inc. HJG has received travel grants and speakers’ honoraria from Fresenius Medical Care, Servier, Neuraxpharm and Janssen Cilag. HJG has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care, the EU "Joint Programme Neurodegenerative Disorders (JPND) and the European Social Fund (ESF)". G.K. is co-inventor (through Duke University/Helmholtz Zentrum München) on patents on applications of metabolomics in diseases of the central nervous system; G.K. holds equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in depression. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
